最近最经典中文mv字幕-最近韩国电影免费高清hd-最近的中文字幕大全免费-最近日韩中文字幕中文翻译歌词

您好,歡迎來到上海士研管理咨詢有限公司
產業峰會 演講局 專家智庫服務 峰會活動服務 整合營銷服務
  • 產業峰會:
    以專業團隊對產業和市場客觀詳實地調研為前提,擁有戰略性、系統性、全球性的基因,匯集了領導者關注的熱點話題與領袖代表,為您提供“一站式”的對話、分享、社交平臺!
  • 演講局:
    致力于為全球企業和機構提供主題演講家、高管大師班、董事會顧問,每項服務都提供了一種更深入、更具互動性的體驗,尤其是針對較小的精選受眾和關鍵個人。我們擁有最具影響力的商業領袖和頂級專家的資源,他們是各自領域的最杰出的代表。我們的團隊由經驗豐富的演講和活動經理組成,我們注重建立長期而深入的伙伴關系。
  • 專家智庫服務:
    中國領先的行業專家知識信息服務供應商,為需要專業洞見的商業決策者匹配具有一手經驗的行業專家,助力他們以更加明確的目標和堅定的信心做出決策。我們有60萬余名專家顧問遍布二十多個行業,而且每天還在增加!
  • 峰會活動服務:
    致力于成為全球最專業的產業峰會活動提供商,為企業和機構的產業性峰會活動提供一站式專業服務,包括調研策劃、定制邀請、營銷推廣、運營組織、項目管理、直播與數字化會議等,每項服務都由經驗豐富的專業團隊匹配長期沉淀的產業資源予以卓越執行,我們注重建立長期而深入的伙伴關系。
  • 整合營銷服務:
    致力于成為全球領先的2B營銷服務機構,聚焦產業高端活動、內容、渠道的建設與沉淀,為客戶提供一站式整合營銷解決方案,助力企業線上線下獲客與品牌筑造。我們深信專業團隊匹配產業資源帶來卓越執行,我們注重建立長期而深入的伙伴關系。
嘉賓信息
發布時間: 2023 - 06 - 25
點擊次數: 0
所屬職位: 首席執行官
所屬公司: 邦耀生物
個人簡介:
鄭彪博士畢業于浙江大學醫學院醫學系;獲上海復旦大學醫學院免疫學碩士及倫敦大學 (King’s College, University of London) 免疫學博士學位。曾在美國馬里蘭大學醫學院 (University of Maryland School of Medicine) 及杜克大學醫學中心 (Duke University Medical Center) 任教。隨后任職于美國貝勒醫學院 (Baylor College of Medicine), 為該校病理和免疫系終身教授。在葛蘭索史克 (GlaxoSmithKline) 研發中心負責免疫學研究工作。曾任美國強生公司(Janssen Pharmaceuticals, Johnson & Johnson) 全球副總裁, 負責亞太地區免疫領域創新藥物研發,包括免疫調節機制、腫瘤免疫、及自身免疫性疾病。鄭彪博士現任邦耀生物首席執行官。鄭彪教授學術著作豐厚,其中多篇發表在Nature和Science等世界頂尖雜志上。在馬里蘭大學、杜克大學及貝勒醫學院工作期間獲得多項重大科研基金,包括美國NIH科研基金、白血病與淋巴瘤協會基金、美國關節炎基金會、美國心臟研究協會基金、美國衰老研究聯盟基金等。在藥物研發方面,從新藥篩選、靶點研究、疾病模型、臨床前及臨床試驗等方面積累了重要的經驗,對新藥開發全過程有深刻的認識。在打造小分子藥,大分子抗體藥,細胞治療管線均有豐富的經驗。Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center. He was a tenured professor in the Department of Pathology and Immunology, Baylor College of Medicine. Dr. Zheng worked for GlaxoSmithKline R&D Center as the head of Immunological Discovery Sciences. He was a global vice president of the Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, responsible for the innovative immunological drug pipeline in the region. Dr. Zheng is now the Chief Executive Officer at BRL Medicine.Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
發布時間: 2023 - 06 - 25
點擊次數: 0
所屬職位: 副總裁
所屬公司: 蘇州開拓藥業
個人簡介:
許若博士本科就讀于北京大學化學系,之后獲美國哥倫比亞大學博士學位。從1998年開始,許博士先后在先靈堡雅、默克、API Inc.等美國大小制藥企業的工作20多年,在藥物化學,工藝化學,原料藥的cGMP制造,CMC文件準備和提交等領域積累了豐富的經驗。許博士于2019年4月回國加入開拓藥業股份有限公司,擔任化學副總裁職務。全面負責公司的藥物化學的研發和原料藥的生產工作。Dr. Xu received his bachelor's degree in chemistry from Peking University and his Ph.D. from Columbia University. After his academic training, Dr. Xu has worked in pharmaceutical industry for more than 20 years, including Schering-Plough, Merck, API Inc. etc. in the United States. During this time, he accumulated rich experience in medicinal chemistry, process chemistry, cGMP manufacturing of APIs, CMC document preparation and submission, etc. Dr. Xu returned to China in April 2019 and joined Kintor Pharma as Vice President of Chemistry. He is responsible for the medicinal chemistry research and the production of APIs of the company.
發布時間: 2023 - 06 - 25
點擊次數: 0
所屬職位: 創始人、董事長兼總經理
所屬公司: 宜明昂科生物醫藥技術(上海)股份有限公司
個人簡介:
田文志博士,上海市“千人計劃”專家、浦東新區“百人計劃”專家、科技部火炬中心科技創新創業人才、復旦大學藥學院兼職教授,現任宜明昂科生物醫藥技術(上海)股份有限公司董事長兼總經理。于1995年10月至2011年4月先后在瑞典、美國留學及工作,主要從事腫瘤免疫學及抗腫瘤抗體藥物開發研究。累計發表學術論文30余篇,克隆新基因7個,參編英文專著一部,申請新藥發明專利40余項,獲得授權13項。2011年4月辭職回國,先后創辦了華博生物醫藥技術(上海)有限公司、宜明昂科生物醫藥技術(上海)股份有限公司及宜明探科生物醫藥技術(上海)有限公司。回國12年以來,已將 8個新藥項目開發至臨床試驗階段,其中7項已開展臨床試驗。Dr. Wenzhi Tian is the founder and Chairman of IImmuneOnco Biopharmaceuticals (Shanghai) Inc., a clinical stage biotech company headquartered in Shanghai, China, with primary focus on research and development of tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANKTM) products. Prior to ImmuneOnco Biopharma, Dr. Tian worked as Chief Executive Officer at Huabo Biopharm from June of 2011 to April of 2015. During that period, Dr. Tian advanced two large molecule programs to the clinical stage. Prior to moving back to China, Dr. Tian worked as Principal Research Scientist at ImClone Systems from January of 2006 to April of 2011. Dr. Tian graduated from Henan Medical University (Now Zhengzhou University School of Medicine) and did his postdoctoral training at North Shore University Hospital, NYU School of Medicine. He was appointed a Senior Research Associate at Weill Medical College of Cornell University thereafter.
發布時間: 2023 - 06 - 25
點擊次數: 0
所屬職位: 執行董事、首席執行官
所屬公司: 蘇州創勝醫藥集團有限公司
個人簡介:
錢雪明博士是創勝集團醫藥有限公司(下稱創勝集團)的首席執行官。創勝集團是一家具備生物藥發現、研發、工藝開發和生產全流程整合能力的臨床階段的生物制藥公司。2021年9月29日,創勝集團在香港聯合交易所主板上市,股票代碼:06628。錢雪明博士畢業于復旦大學生物物理學系 (1985 – 1990),并分別在哥倫比亞大學 (Columbia University, 1990 – 1992) 和奧爾巴尼醫學中心 (Albany Medical Center, 1995 – 1997) 獲得神經學與生理學碩士學位和神經學與藥理學博士學位。錢雪明博士擁有 20 年的生物制藥行業經驗。在創立創勝集團之前,錢博士于 2010-2013 年間任盛諾基醫藥集團 (Shenogen Pharma Group) 研發總裁和董事會成員。1997-2010 間任職于美國安進公司,專注于抗體新藥的開發。錢博士是十多個創新藥物專利申請的發明人,也是國際抗體協會會員、國際腎病協會會員、新藥創始人俱樂部、創新生物社和 BayHelix 百華協會會員,獲得了國家級高層次人才、蘇州工業園區科技領軍人才和蘇州市姑蘇創新創業領軍人才等支持。Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics. Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder’s Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR, ASN and Antibody Society.
微信公眾號
領導者網絡APP
友情鏈接
Copyright ?2005 - 2017上海士研管理咨詢有限公司
犀牛云提供企業云服務